CClinicalTrials.gg
RecruitingNCT06223217Updated Jan 25, 2024

Development and Validation of the Modified Version of VascuQol Scale in Patients With Lower Extremity Peripheral Arterial Disease.

An observational study in Peripheral Arterial Disease, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by RenJi Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
480
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The purpose of this study is to assess the utility of the Modified version of VascuQol Scale as an effective biopsychosocial assessment tool for patients suffering from lower extremity peripheral arterial disease.

Read the detailed description

In the prior study, the original 25-item VascuQol Scale demonstrates the limitation of dimensional mixing. As a result, we suggest improving the original scale by integrating the five dimensions and simplifying the objects. 480 patients will be recruited to complete the Chinese version of VascuQol Scale and the modified version. Reliability, validity, responsiveness, and diagnostic accuracy for CLTI will be used to evaluate whether the modified scale could serve as an effective biopsychosocial assessment tool for patients suffering from lower extremity peripheral arterial disease.

Study Procedures :

After signing the informed consent form, eligible patients and/or their legal guardians will complete the questionnaires.

Outcome measures:

Patient-Reported Outcomes via specific questionnaires

Participant numbers:

480 patients will be recruited

Data management:

Data will be collected directly from the patients. All paper patient records will be kept in locked filing cabinet. Electronic files will be saved on password protected folder

Oversight :

i) Data will be collected in a electric database; ii) all documents containing the identity of the participating subjects (non-objection, list of correspondence, etc.) will be kept away from personal data; iii) If it is a computerized document, it will be kept on the center's information server with access control by password.

02

Conditions studied

03

In context

Peripheral Arterial Disease

1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.

This study's planned enrollment of 480 is above the median of 190 across 410 observational studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patient is diagnosed with lower extremity peripheral arterial disease and no restrictions on Rutherford grading, TASC grading, GLASS grading.

Inclusion criteria

  1. Male or female aged 18-90
  2. The patient is diagnosed with lower extremity peripheral arterial disease
  3. The patient is willing to comply with specified follow-up evaluations at the specified times
  4. The patient understands the nature of the procedure and provides written informed consent before enrolment in the study
  5. Before enrolment, the guidewire has crossed the target lesion
  6. No restrictions on Rutherford grading, TASC grading, GLASS grading

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women or Female patients with potential childbearing
  2. The patient is currently participating in another investigational drug or device study that has not reached the primary endpoint.
  3. Patients unwilling or refusing to sign informed consent
  4. Patients with other diseases that may seriously affect the quality of life, such as tumors, severe liver disease, cardiac insufficiency, etc., or those with a life expectancy of less than 2 years
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
480 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experiment group

    Patients who undergoing endoluminal treatment for lower extremity peripheral arterial disease will complete the Modified version of the VascuQoL scale, the Chinese version of the VascuQoL scale, EQ-5D-5L Scale and the ABI test according to follow-up plan.

    Other: Surveys and Questionnaires

Interventions

  • OtherSurveys and Questionnaires

    The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale

06

What researchers measure

Primary outcomes

  1. the Modified version of VascuQol Scale

    It is one of the frequently used scales to measure quality of life in patients with lower extremity arterial disease. It evaluates 5 different categories such as the symptom, social, activity, pain and emotional with a total of 25 sub-items. A 7-point Likert system is used to score this scale. It is sufficient for each item to check the corresponding boxes. In Modified version,we adjusted the questionnaire items and structure based on the the Chinese version and results of the previous reserach.

    Time frame: pre-operation;1-month;3-month;6-month;12-month

  2. the Chinese version of VascuQol Scale

    It is one of the frequently used scales to measure quality of life in patients with lower extremity arterial disease. It evaluates 5 different categories such as the symptom, social, activity, pain and emotional with a total of 25 sub-items. A 7-point Likert system is used to score this scale. It is sufficient for each item to check the corresponding boxes. In Chinese version,not only did we complete cultural adaptation, but we used the emoji-based visual analogue scale to help patients fill out the scales.

    Time frame: pre-operation;1-month;3-month;6-month;12-month

Secondary outcomes

  1. Ankle brachial index(ABI)

    The ankle-brachial index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium). Compared to the arm, lower blood pressure in the leg suggests blocked arteries due to peripheral artery disease (PAD). The ABPI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.

    Time frame: pre-operation;6-month;12-month

  2. EQ-5D-5L Scale

    EQ-5D is a standardised measure of health-related quality of life developed by the EuroQol Group to provide a simple, generic questionnaire for use in clinical and economic appraisal and population health surveys. EQ-5D assesses health status in terms of five dimensions of health and is considered a 'generic' questionnaire because these dimensions are not specific to any one patient group or health condition.

    Time frame: pre-operation;1-month;3-month;6-month;12-month

07

Study locations

1 of 1 sites recruiting
  • Renji Hospital
    Shanghai, Shanghai, China
    • Jingpu Zhu · Contact · a8600809@163.com · +86-17520505530
    • Lan Zhang, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06223217
Lead sponsor
RenJi Hospital
Collaborators
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology, First Affiliated Hospital of Zhejiang University, First People's Hospital of Hangzhou, Huashan Hospital, Hospital of Chengdu University of TCM
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Oct 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 25, 2024

Study contacts

Jingpu Zhu
Contact
a8600809@163.com
+86-17520505530

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion